SCHEMBL21643832

SCHEMBL21643832

C#Cc1c(C(=O)OC)cc([N+](=O)[O-])c(Cl)c1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.43
FGFR1 P11362 1/20 0.43
PDGFRA P16234 1/20 0.43
FLT1 P17948 1/20 0.43
FGFR3 P22607 1/20 0.43
KDR P35968 1/20 0.43
GPR35 Q9HC97 1/20 0.43
TDP1 Q9NUW8 1/20 0.41
COMT P21964 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.38
POLB P06746 2/20 0.38
MAPT P10636 2/20 0.38
SIRT6 Q8N6T7 1/20 0.38
ERN1 O75460 2/20 0.38
LMNA P02545 3/20 0.37
G6PD P11413 1/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21643828 0.81 GPR35 (0.45) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL15823299 0.80 PDGFRB (0.42) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL8064653 0.76 PDGFRB (0.48) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL15996997 0.76 PDGFRB (0.51) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL12000739 0.74 TDP1 (0.49) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL32659719 0.73 PDGFRB (0.51) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL24100061 0.73 TDP1 (0.48) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL1786384 0.73 TDP1 (0.51) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL6626231 0.73 ALDH1A1 (0.46) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL2310798 0.73 TDP1 (0.48) PDGFRBFGFR1PDGFRAFLT1FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12129267-B2 Heteroaryl amide compounds as sting activators INCYTE CORPORATION (US) 2024-10-29 US disclosed
US-20230398225-A1 PD-L1/STING CONJUGATES AND METHODS OF USE INCYTE CORPORATION 2023-12-14 US disclosed
US-20230398225-A1 PD-L1/STING CONJUGATES AND METHODS OF USE INCYTE CORPORATION 2023-12-14 US disclosed
US-20230398225-A1 PD-L1/STING CONJUGATES AND METHODS OF USE INCYTE CORPORATION 2023-12-14 US disclosed
US-11596692-B1 PD-L1/STING conjugates and methods of use INCYTE CORPORATION (US) 2023-03-07 US disclosed
US-11596692-B1 PD-L1/STING conjugates and methods of use INCYTE CORPORATION (US) 2023-03-07 US disclosed
US-11427597-B2 Heteroaryl amide compounds as sting activators INCYTE CORPORATION (US) 2022-08-30 US disclosed
US-20220056049-A1 HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS INCYTE CORPORATION 2022-02-24 US disclosed
US-20210163493-A1 HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS INCYTE CORPORATION 2021-06-03 US disclosed
US-20210163493-A1 HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS INCYTE CORPORATION 2021-06-03 US disclosed
US-10875872-B2 Heteroaryl amide compounds as sting activators INCYTE CORPORATION (US) 2020-12-29 US disclosed
US-10875872-B2 Heteroaryl amide compounds as sting activators INCYTE CORPORATION (US) 2020-12-29 US disclosed
WO-2020146237-A1 HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS INCYTE CORPORATION (US) 2020-07-16 WO disclosed
WO-2020146237-A1 HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS INCYTE CORPORATION (US) 2020-07-16 WO disclosed
US-20200039994-A1 HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS INCYTE CORPORATION 2020-02-06 US disclosed
WO-2020028566-A1 HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS INCYTE CORPORATION (US) 2020-02-06 WO disclosed
WO-2020028566-A1 HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS INCYTE CORPORATION (US) 2020-02-06 WO disclosed
US-20200039994-A1 HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS INCYTE CORPORATION 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12129267-B2 Heteroaryl amide compounds as sting activators STING1, MAVS, IRF3 PDGFRB 742/4885FGFR1 3628/4885PDGFRA 486/4885
US-20220056049-A1 HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS STING1, MAVS, IRF3 PDGFRB 742/4885FGFR1 3628/4885PDGFRA 486/4885
US-11596692-B1 PD-L1/STING conjugates and methods of use STING1, PDCD1LG2, CD274 PDGFRB 861/4885FGFR1 2086/4885PDGFRA 932/4885
US-20230398225-A1 PD-L1/STING CONJUGATES AND METHODS OF USE STING1, PDCD1LG2, CD274 PDGFRB 861/4885FGFR1 2086/4885PDGFRA 932/4885
US-10875872-B2 Heteroaryl amide compounds as sting activators STING1, MAVS, IRF3 PDGFRB 742/4885FGFR1 3628/4885PDGFRA 486/4885
US-11427597-B2 Heteroaryl amide compounds as sting activators STING1, MAVS, IRF3 PDGFRB 742/4885FGFR1 3628/4885PDGFRA 486/4885
US-20210163493-A1 HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS STING1, MAVS, IRF3 PDGFRB 742/4885FGFR1 3628/4885PDGFRA 486/4885
US-20200039994-A1 HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS STING1, MAVS, IRF3 PDGFRB 742/4885FGFR1 3628/4885PDGFRA 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.